Opinion|Videos|July 30, 2024
Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
- Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
- How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
- OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
- Currently, can you assay B7-H3 to determine individual expression levels?
- How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
- amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
- topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
- lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
- What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?
Advertisement
Related to this article
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5